KIYATEC Revenue and Competitors

Location

N/A

Total Funding

3D

Industry

Estimated Revenue & Valuation

  • KIYATEC's estimated annual revenue is currently $4.1M per year.(i)
  • KIYATEC's estimated revenue per employee is $136,000

Employee Data

  • KIYATEC has 30 Employees.(i)
  • KIYATEC grew their employee count by -3% last year.

KIYATEC's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
VP, Market Access & ReimbursementReveal Email/Phone
4
Human Resources DirectorReveal Email/Phone
5
Director R&D, Contract ServicesReveal Email/Phone
6
Director Research & Development - Immuno-oncologyReveal Email/Phone
7
Chief Commercial OfficerReveal Email/Phone
8
Chief Scientific OfficerReveal Email/Phone
9
Communications ManagerReveal Email/Phone
10
Clinical Affairs ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M1614%N/AN/A
#2
$4.1M30-3%N/AN/A
#3
$0.7M18-22%$5MN/A
#4
$637.4M30735%$264.2MN/A
Add Company

What Is KIYATEC?

Wasted time is the enemy of cancer patients. KIYATEC's mission is to change the future of cancer care by accurately predicting patient-specific response and non-response before treatment begins. We utilize the patient's own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and the NCI. We are conducting robust clinical trials to fully demonstrate the power of our approach and earn widespread adoption for a broad portfolio of products predicting response to today's and tomorrow's therapies. www.kiyatec.com

keywords:N/A

N/A

Total Funding

30

Number of Employees

$4.1M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

KIYATEC News

2022-03-30 - CORRECTING and REPLACING KIYATEC and ACCRF Joint ...

CORRECTING and REPLACING KIYATEC and ACCRF Joint Abstract at AACR Highlights Use of KIYA-PREDICT™ Drug Response Platform in ACC. CORRECTION…by...

2022-03-22 - KIYATEC Announces Key Appointments in Market Access ...

KIYATEC is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.5M30-12%N/A
#2
$6.1M300%N/A
#3
$5.4M303%N/A
#4
$6.5M307%N/A
#5
$2.4M303%N/A